The innate immune system employs germline-encoded pattern recognition receptors to survey the extra- and intra-cellular milieu for the presence of invading microbial or danger signals and mount appropriate defense responses. Inflammasomes, the multiprotein complexes assembled in the cytosol in response to microbial and endogenous danger signals, have emerged as a central component of the innate immune surveillance system. Once assembled inflammasomes proteolytically activate caspase-1, which in turn induces cell death and production of IL-1? and IL-18. Most recently a noncanonical NLRP3 inflammasome pathway was identified that is activated by LPS that enters the cytosol via outer membrane vesicles during infection with Gram-negative bacteria such as Enterohemorrhagic E. coli (EHEC). Cytosolic LPS binds and activates an inflammatory caspase, caspae-11, which then mediates cell death, caspase-1 activation and downstream IL-1 cytokine production. Inflammasomes, including the caspase-11-mediated noncanonical inflammasome, play a crucial role in the clearance of infectious agents via pyroptotic and IL-1 responses. A strong selection pressure from the host such as this drives pathogens to develop strategies to actively antagonize or evade innate immune responses. However, little is known about regulation of caspase-11- mediated noncanonical inflammasome by bacterial pathogens. This project will address this knowledge gap and will focus on examining the modulation of noncanonical inflammasome by bacteria utilizing EHEC as a model organism. The studies proposed in the three specific aims of this project will systematically characterize how two bacterial virulence factors inhibit the noncanonical inflammasome and determine the underlying mechanisms. Identifying the mechanisms by which pathogenic bacteria silence noncanonical inflammasome is crucial as it may aid in designing novel therapeutic approaches against Gram-negative infections.
. Enterohemorrhagic Escherichia coli (EHEC) is the causative agent of hemorrhagic colitis and life threatening hemolytic uremic syndrome that affects 96,000 people annually in the United States. Treatment options for EHEC infections are limited as antibiotics increases the severity of the disease and therefore are contraindicated. A major innate immune signaling pathway that can sense EHEC and potentially clear the infection is the noncanonical inflammasome pathway. The proposed study aims to identify the mechanisms by which EHEC inhibits this noncanonical inflammasome pathway, which may aid in designing novel immunomodulatory therapeutic approaches against EHEC.
